Bioterrorism
Morphotek Receives $2.7M in Funding from the National Institute of Allergy and Infectious Diseases to Develop Therapeutic Antibodies Against Biowarfare Agents
Published in TB and Outbreaks Week, October 16th, 2007
Morphotek, Inc., a subsidiary of Eisai Co., Ltd. announced that the company has received $2.7M in funding from the National Institute of Allergy and Infectious Diseases (NIAID) to support the preclinical development of fully human therapeutic monoclonal antibodies (mAbs) capable of neutralizing the toxic effects of Staphylococcal enterotoxin B (SEB) in vivo. The development project is a defense initiative in the fight against biowarfare agents.
The funding will be used to develop potent therapeutic mAbs capable of suppressing the toxic effects of SEB with the goal of demonstrating proof-of-concept in clinical trials. By employing Morphotek's proprietary human...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Bird Flu
Researchers Identify Key Step Bird Flu Virus Takes to Spread Readily in Humans - Ebola Hemorrhagic Fever
The reservoir of Marburg virus identified in a species of fruit bat - Hygiene
Want to Stop Flu? Focus on Children's Hygiene - Leishmaniasis
New system to lead to safer drugs for tropical disease leishmaniasis - Bioterrorism
Novel Approaches to the Study, Surveillance and Control of Infectious Diseases - Bioterrorism
Origen Therapeutics Receives $2 Million ATP Grant to Advance Technology for Discovery and Production of Human Polyclonal Antibodies from Transgenic Chickens - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
